Alterations in drug disposition in older adults: a focus on geriatric syndromes

References

• World Health Organization. World report on ageing and health. Geneva, Switzerland: World Health Organization; 2015.
   Google Scholar
• Moore KL, Patel K, John Boscardin W, et al. Medication burden attributable to chronic comorbid conditions in the very old and vulnerable. PLoS One. 2018;13(4):e0196109.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995.
   PubMed Web of Science ®Google Scholar
• Davies LE, Spiers G, Kingston A, et al. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181–187.
   PubMed Web of Science ®Google Scholar
• Ruiter R, Burggraaf J, Rissmann R. Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the food and drug administration database. Br J Clin Pharmacol. 2019;85(4):838–844.
   PubMed Web of Science ®Google Scholar
• Fialova D, Laffon B, Marinkovic V, et al. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies). Eur J Clin Pharmacol. 2019;75(4):451–466.
   PubMed Web of Science ®Google Scholar
• Chetty M, Johnson TN, Polak S, et al. Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Adv Drug Deliv Rev. 2018;135:85–96.
   PubMed Web of Science ®Google Scholar
• Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11(4):491–508.
   PubMed Web of Science ®Google Scholar
• Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016;43(5):481–504.
   PubMed Web of Science ®Google Scholar
• Hamczyk MR, Nevado RM, Barettino A, et al. Biological Versus Chronological Aging JACC Focus Seminar. J Am Coll Cardiol. 2020;75(8):919–930.
   PubMed Web of Science ®Google Scholar
• Magnuson A, Sattar S, Nightingale G, et al. A practical guide to geriatric syndromes in older adults with cancer: a focus on falls, cognition, polypharmacy, and depression. Am. 2019;39:e96–e109.
   Google Scholar
• Inouye SK, Studenski S, Tinetti ME, et al. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–791.
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.
   PubMed Web of Science ®Google Scholar
• Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people-How to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol. 2019;19:19.
   Google Scholar
• Soenen S, Rayner CK, Jones KL, et al. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19(1):12–18.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Williams DB, Upton RN, et al. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 2017;112:234–248.
   PubMed Web of Science ®Google Scholar
• Patel D, Bertz R, Ren S, et al. Review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet. 2020;59(4):447–462.
   PubMed Web of Science ®Google Scholar
• Dumic I, Nordin T, Jecmenica M, et al. Gastrointestinal tract disorders in older age. Can J Gastroenterol Hepatol. 2019;2019:6757524.
   PubMed Web of Science ®Google Scholar
• Merchant HA, Liu F, Orlu Gul M, et al. Age-mediated changes in the gastrointestinal tract. Int J Pharm. 2016;512(2):382–395.
   PubMedGoogle Scholar
• Russell RM. Changes in gastrointestinal function attributed to aging. Am J Clin Nutr. 1992;55(6Suppl):1203S–7S.
   PubMedGoogle Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
   PubMed Web of Science ®Google Scholar
• Thurmann PA. Pharmacodynamics and pharmacokinetics in older adults. Curr Opin Anaesthesiol. 2020;33(1):109–113.
   PubMed Web of Science ®Google Scholar
• Jain R, Chung S, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89.
   PubMed Web of Science ®Google Scholar
• Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs - Implications for therapy. Clin Pharmacokinet. 2000;38(3):271–290.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377(1–2):1–13.
   PubMed Web of Science ®Google Scholar
• Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26(2):144–160.
   PubMed Web of Science ®Google Scholar
• Tan JL, Eastment JG, Poudel A, et al. Age-related changes in hepatic function: an update on implications for drug therapy. Drugs Aging. 2015;32(12):999–1008.
   PubMed Web of Science ®Google Scholar
• Stader F, Siccardi M, Battegay M, et al. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet. 2019;58(4):483–501.
   PubMed Web of Science ®Google Scholar
• Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(5):297–321.
   PubMed Web of Science ®Google Scholar
• Waring RH, Harris RM, Mitchell SC. Drug metabolism in the elderly: A multifactorial problem? Maturitas. 2017;100:27–32.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Patel F, Jensen BP, et al. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol. 2013;75(4):1019–1028.
   PubMed Web of Science ®Google Scholar
• Cohen E, Nardi Y, Krause I, et al. A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol. 2014;27(6):635–641.
   PubMed Web of Science ®Google Scholar
• Bolignano D, Mattace-Raso F, Sijbrands EJG, et al. The aging kidney revisited: A systematic review. Ageing Res Rev. 2014;14:65–80.
   PubMed Web of Science ®Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28.
   PubMed Web of Science ®Google Scholar
• Pea F. Pharmacokinetics and drug metabolism of antibiotics in the elderly. Expert Opin Drug Metab Toxicol. 2018;14(10):1087–1100.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sun B, Zhang L, et al. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clin Pharmacol Ther. 2016;100(1):75–87.
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–1074.
   PubMed Web of Science ®Google Scholar
• Tan ML, Yoshida K, Zhao P, et al. Effect of Chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103(5):854–867.
   PubMed Web of Science ®Google Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people: Europe PMC funders; 2013.
   Google Scholar
• Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol Ser A. 2007;62(7):722–727.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Wu H, Zhang M. Biology of frailty: implications for clinical pharmacology and drug therapy in frail older people. Mech Ageing Dev. 2019;181:22–28.
   PubMed Web of Science ®Google Scholar
• Hubbard RE, O’Mahony MS, Savva GM, et al. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9b):3103–3109.
   PubMed Web of Science ®Google Scholar
• Chang SS, Weiss CO, Xue QL, et al. Association between inflammatory-related disease burden and frailty: results from the women’s health and aging studies (WHAS) I and II. Arch Gerontol Geriatr. 2012;54:9–15.
   PubMed Web of Science ®Google Scholar
• Hughes K, Lang J, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 1992;22(7):859–869.
   PubMed Web of Science ®Google Scholar
• Van Tongeren SP, Slaets JPJ, Harmsen HJM, et al. Fecal microbiota composition and frailty. Appl Environ Microbiol. 2005;71:6438–6442.
   PubMed Web of Science ®Google Scholar
• Marzetti E, Calvani R, Tosato M, et al. Sarcopenia: an overview. Aging Clin Exp Res. 2017;29(1):11–17.
   PubMed Web of Science ®Google Scholar
• Buch A, Carmeli E, Boker LK, et al. Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age—an overview. Exp Gerontol. 2016;76:25–32.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Tran K, Rubie P, et al. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011;71:224–231.
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Blyth FM, Creasey HM, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65:712–717.
   PubMed Web of Science ®Google Scholar
• Hubbard RE, O’Mahony MS, Calver BL, et al. Nutrition, inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc. 2008;56:279–284.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Dayton PG. HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS †,‡. Drug Metab Rev. 2001;33:161–235.
   PubMed Web of Science ®Google Scholar
• Reeve E, Trenaman SC, Rockwood K, et al. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–668.
   PubMed Web of Science ®Google Scholar
• Roberts J, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1–8.
   PubMed Web of Science ®Google Scholar
• Morgan E. Impact of infectious and inflammatory disease on cytochrome P450–mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–438.
   PubMed Web of Science ®Google Scholar
• Hubbard RE, O’Mahony MS, Calver BL, et al. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64:895–900.
   PubMed Web of Science ®Google Scholar
• Abou-Hatab K, O’Mahony MS, Patel S, et al. Relationship between age and plasma esterases. Age Ageing. 2001;30:41–45.
   PubMed Web of Science ®Google Scholar
• Dumond J, Chen J, Cottrell M, et al. Population pharmacokinetics modeling of unbound Efavirenz, Atazanavir, and Ritonavir in HIV-infected subjects with aging biomarkers. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):128–135.
   PubMedGoogle Scholar
• Wynne H. Drug metabolism and ageing. J Br Menopause Soc. 2005;11:51–56.
   PubMedGoogle Scholar
• Wynne H, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19:419–424.
   PubMed Web of Science ®Google Scholar
• Wynne HA, Yelland C, Cope LH, et al. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing. 1993;22:354–360.
   PubMed Web of Science ®Google Scholar
• Johnston C, Hilmer SN, McLachlan AJ, et al. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70:549–555.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Stehman-Breen C, Fried LF, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004;43:861–867.
   PubMed Web of Science ®Google Scholar
• Kane AE, Mitchell SJ, Mach J, et al. Acetaminophen hepatotoxicity in mice: effect of age, frailty and exposure type. Exp Gerontol. 2016;73:95–106.
   PubMed Web of Science ®Google Scholar
• Mitchell SJ, Hilmer SN, Murnion BP, et al. Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Ther. 2011;36:327–335.
   PubMed Web of Science ®Google Scholar
• Cullinan S, O’Mahony D, O’Sullivan D, et al. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. Age Ageing. 2016;45:115–120.
   PubMed Web of Science ®Google Scholar
• Herr M, Robine J-M, Pinot J, et al. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24:637–646.
   PubMed Web of Science ®Google Scholar
• Bonaga B, Sánchez-Jurado PM, Martínez-Reig M, et al. Frailty, polypharmacy, and health outcomes in older adults: the frailty and dependence in albacete study. J Am Med Dir Assoc. 2018;19:46–52.
   PubMed Web of Science ®Google Scholar
• Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open. 2019;9:5.
   Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:16–31.
   Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646.
   PubMed Web of Science ®Google Scholar
• Williams GR, Deal AM, Shachar SS, et al. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol. 2018;81(2):413–417.
   PubMed Web of Science ®Google Scholar
• Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases. 2020;8(7):1188–1202.
   PubMed Web of Science ®Google Scholar
• Association As. Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2015;2015(11):332–384.
   Google Scholar
• Jin L, Pan Y, Tran NLL, et al. Intestinal permeability and oral absorption of selected drugs are reduced in a mouse model of familial Alzheimer’s disease. Mol Pharm. 2020;17(5):1527–1537.
   PubMedGoogle Scholar
• Pan Y, Omori K, Ali I, et al. Altered expression of small intestinal drug transporters and hepatic metabolic enzymes in a mouse model of familial Alzheimer’s disease. Mol Pharm. 2018;15(9):4073–4083.
   PubMedGoogle Scholar
• Ahmed AIA, Van Den Elsen GAH, Colbers A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl). 2015;232:2587–2595.
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer’s disease. Clin Ther. 1998;20(4):634–647.
   PubMed Web of Science ®Google Scholar
• Gillette Guyonnet SAVKG, Alix E, Andrieu S, et al. International Academy on Nutrition and Aging Expert Group. IANA (International Academy on Nutrition and Aging) expert group: weight loss and Alzheimer’s disease. J Nutr Health Aging. 2007;11:38–48.
   PubMed Web of Science ®Google Scholar
• Maes M, DeVos N, Wauters A, et al. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer’s disease. J Psychiatr Res. 1999;33:397–405.
   PubMed Web of Science ®Google Scholar
• Duarte P, Duarte M, Pelichek A, et al. Cardiovascular risk factors and inflammatory activity among centenarians with and without dementia. Aging Clin Exp Res. 2017 Jun;29(3):411–417.
   Web of Science ®Google Scholar
• Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics. 2004;4:244–256.
   PubMed Web of Science ®Google Scholar
• German DC, Gurnani P, Nandi A, et al. Serum biomarkers for Alzheimer’s disease: proteomic discovery. Biomed Pharmacothe. 2007;61:383–389.
   PubMed Web of Science ®Google Scholar
• Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis; 2009.
   Google Scholar
• Janelidze S, Hertze J, Nägga K, et al. Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging. 2017;51:104–112.
   PubMed Web of Science ®Google Scholar
• van Assema DME, Lubberink M, Bauer M, et al. Blood-brain barrier P-glycoprotein function in Alzheimer’s disease. Brain. 2012;135:181–189.
   PubMed Web of Science ®Google Scholar
• Deo AK, Borson S, Link JM, et al. Activity of P-glycoprotein, a β-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med. 2014;55:1106–1111.
   PubMed Web of Science ®Google Scholar
• Mehta DC, Short JL, Hilmer SN, et al. Drug access to the central nervous system in Alzheimer’s disease: preclinical and clinical insights. Pharm Res. 2015;32:819–839.
   PubMed Web of Science ®Google Scholar
• Pan Y, Omori K, Ali I, et al. Increased expression of renal drug transporters in a mouse model of familial Alzheimer’s disease. J Pharm Sci. 2019;108(7):2484–2489.
   PubMed Web of Science ®Google Scholar
• Schubert CC, Boustani M, Callahan CM, et al. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc. 2006;54:104–109.
   PubMed Web of Science ®Google Scholar
• Zuliani G, Galvani M, Sioulis F, et al. Discharge diagnosis and comorbidity profile in hospitalized older patients with dementia. Int J Geriatr Psychiatry. 2012;27:313–320.
   PubMed Web of Science ®Google Scholar
• Ali I, Guidone D, Nicolazzo JA, et al. Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia. Br J Clin Pharmacol. 2019;85(10):2351–2359.
   PubMed Web of Science ®Google Scholar
• Jyrkkä J, Enlund H, Korhonen MJ, et al. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging. 2009;26(6):493–503.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86–88.
   PubMed Web of Science ®Google Scholar
• Thomsen LA, Winterstein AG, Søndergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411–1426.
   PubMed Web of Science ®Google Scholar
• Huizer-Pajkos A, Kane AE, Howlett SE, et al. Adverse geriatric outcomes secondary to polypharmacy in a mouse model: the influence of aging. J Gerontol A Biol Sci Med Sci. 2016;71(5):571–577.
   PubMed Web of Science ®Google Scholar
• Hurwitz A, Brady DA, Schaal SE, et al. Gastric acidity in older adults. JAMA. 1997;278(8):659–662.
   PubMed Web of Science ®Google Scholar
• Soenen S, Rayner CK, Horowitz M, et al. Gastric Emptying in the Elderly. Clin Geriatr Med. 2015;31(3):339–353.
   PubMed Web of Science ®Google Scholar
• Bohnert T, Gan LS. Plasma protein binding: from discovery to development. J Pharm Sci. 2013;102(9):2953–2994.
   PubMed Web of Science ®Google Scholar
• Rolan PE. Plasma-protein binding displacement interactions - why are they still regarded as clinically important. Br J Clin Pharmacol. 1994;37(2):125–128.
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Tognini S, Calsolaro V, et al. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–1466.
   PubMed Web of Science ®Google Scholar
• Loboz KK, Shenfield GM. Drug combinations and impaired renal function - the ‘triple whammy’. Br J Clin Pharmacol. 2005;59(2):239–243.
   PubMed Web of Science ®Google Scholar
• Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Med J Aust. 2000;172(4):184–185.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217–230.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Hilmer SN, Le Couteur DG. High-risk prescribing in older people: more harm than good? Aging Health. 2012;8(4):325–327.
   Google Scholar
• Singh S, Hamdy S. Dysphagia in stroke patients. Postgrad Med J. 2006;82(968):383–391.
   PubMed Web of Science ®Google Scholar
• Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347–2357.
   PubMed Web of Science ®Google Scholar
• Jabbar A, McClave SA. Pre-pyloric versus post-pyloric feeding. Clin Nutr. 2005;24(5):719–726.
   PubMed Web of Science ®Google Scholar
• Mundi MS, Patel J, McClave SA, et al. Current perspective for tube feeding in the elderly: from identifying malnutrition to providing of enteral nutrition. Clin Interv Aging. 2018;13:1353–1364.
   PubMed Web of Science ®Google Scholar
• Zhu LL, Zhou Q. Therapeutic concerns when oral medications are administered nasogastrically. J Clin Pharm Ther. 2013;38(4):272–276.
   PubMed Web of Science ®Google Scholar
• Magnuson BL, Clifford TM, Hoskins LA, et al. Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract. 2005;20(6):618–624.
   PubMedGoogle Scholar
• Silva RME, Portela RDP, Da Costa IFR, et al. Immunosuppressives and enteral feeding tubes: an integrative review. J Clin Pharm Ther. 2020;45(3):408–418.
   PubMed Web of Science ®Google Scholar
• Adamji M, Day AS. An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease. Intest Res. 2019;17(2):171–176.
   PubMed Web of Science ®Google Scholar
• Pearson D, May G, Fick GH, et al. Azathioprine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):CD000067.
   Google Scholar
• Sacks GS. Drug-nutrient considerations in patients receiving parenteral and enteral nutrition. Pract Gastroenterol. 2004;28(7):39–49.
   Google Scholar
• Australian Medicines H. Australian medicines handbook: AMH. Adelaide, South Australia: AMH; 2020.
   Google Scholar
• Koren G, Nordon G, Radinsky K, et al. Clinical pharmacology of old age. Expert Rev Clin Pharmacol. 2019;12(8):749–755.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Ebert N, Delanaye P, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157(7):471–U54.
   PubMed Web of Science ®Google Scholar
• Pottel H, Hoste L, Dubourg L, et al. An estimated glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant. 2016;31(5):798–806.
   PubMed Web of Science ®Google Scholar
• Corsonello A, Roller-Wirnsberger R, Wirnsberger G, et al. Clinical implications of estimating glomerular filtration rate with three different equations among older people. Preliminary results of the project “screening for chronic kidney disease among older people across Europe (SCOPE)”. J Clin Med. 2020;9(2):17.
   Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Selistre LD, Rech DL, de Souza V, et al. Diagnostic performance of creatinine-based equations for estimating glomerular filtration rate in adults 65 years and older. JAMA Intern Med. 2019;179(6):796–804.
   PubMed Web of Science ®Google Scholar
• Alshaer IM, Kilbride HS, Stevens PE, et al. External validation of the Berlin equations for estimation of GFR in the elderly. Am J Kidney Dis. 2014;63(5):862–865.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
   PubMed Web of Science ®Google Scholar